No Data
No Data
Chuanning Biotech (301301.SZ): Fully-owned subsidiary Chuanning plans to invest 60 million yuan in industrial fund.
According to Gelonhui on September 27, Chuan Ning Biology (301301.SZ) announced that in order to meet the company's "dual-drive" global strategy needs, expand the company's investment channels, enhance the company's overall competitiveness, expand industrial resources, and develop a reserve of high-quality projects. Without affecting the company's daily operation and development and effectively controlling investment risks, the company's wholly-owned subsidiary Chuan Ning Investment plans to participate in the investment Shanghai Lingang Holdings Da Linghao Bay Qichuang Life Science Private Equity Fund partnership enterprise (limited partnership). The target total amount of subscribed capital of the partnership enterprise is RMB 800 million, and the company will act as the limited partner (LP) of the partnership enterprise who intends to subscribe.
Does Yili Chuanning BiotechnologyLtd (SZSE:301301) Deserve A Spot On Your Watchlist?
Twining Biotech: 2024 Semi-Annual Report Summary
Twining Biotech: 2024 Semi-Annual Report
Chuanning Biological (301301.SZ) released its first-half performance, with a net income increase of 96.05% to 0.766 billion yuan, driven by increases in both product quantity and price.
Chuanning Biological (301301.SZ) released its 2024 interim report. The company's revenue was 31.95 million yuan...
Chuanning Biology (301301.SZ): The net income in the first half of the year was 0.766 billion yuan, an increase of 96.05% year-on-year.
Gelonghui, August 26th, Chuan Ning Bioscience (301301.SZ) released its semi-annual report for 2024, with a reported half-year revenue of 3.195 billion yuan, a year-on-year increase of 32.20%; net income attributable to shareholders of the listed company was 0.766 billion yuan, a year-on-year increase of 96.05%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.766 billion yuan, a year-on-year increase of 95.02%; basic earnings per share was 0.34 yuan.
No Data
No Data